Genentech’s Venclexta (venetoclax) + Azacitidine Receives Breakthrough Therapy Designation for the Treatment of Myelodysplastic Syndromes

 Genentech’s Venclexta (venetoclax) + Azacitidine Receives Breakthrough Therapy Designation for the Treatment of Myelodysplastic Syndromes

Genentech’s Venclexta (venetoclax) + Azacitidine Receives Breakthrough Therapy Designation for the Treatment of Myelodysplastic Syndromes

Shots:

  • The designation is based on interim results from the P-Ib M15-531 study evaluating Venclexta + azacitidine in naïve patients with previously untreated higher-risk MDS
  • The primary objectives of the study are to assess the safety, Pk and determine the RP2D and dosing schedule of Venclexta in combination with azacitidin
  • Venclexta is a novel inhibitor of BCL-2 protein, jointly developed & commercialized by Genentech & Abbvie in the US & commercialized by AbbVie outside of the US. The therapy is also approved in the US & EU in combination with Rituxan for the treatment of CLL & in combination with Gazyva for the treatment of patients with previously untreated CL

Click here to­ read full press release/ article | Ref: Businesswire | Image: Center for Health Journalism

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post